CN111965240A - Product, application and method for thyroid cancer related screening and assessment - Google Patents
Product, application and method for thyroid cancer related screening and assessment Download PDFInfo
- Publication number
- CN111965240A CN111965240A CN201910420650.4A CN201910420650A CN111965240A CN 111965240 A CN111965240 A CN 111965240A CN 201910420650 A CN201910420650 A CN 201910420650A CN 111965240 A CN111965240 A CN 111965240A
- Authority
- CN
- China
- Prior art keywords
- thyroid cancer
- metabolic
- subject
- product
- molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
- G01N27/64—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode using wave or particle radiation to ionise a gas, e.g. in an ionisation chamber
Abstract
The invention provides a product, application and a method for Thyroid Cancer (TC) related screening and evaluation, which are characterized in that body fluid samples of Thyroid Cancer patients and healthy people are mixed with nanosphere materials, metabolic molecule information in related body fluid is collected through matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS), the metabolic molecule spectrum difference of the healthy people and the Thyroid Cancer patients is distinguished through an artificial intelligent classification algorithm, and the difference is classified, so that the distinguishing effect of high accuracy, high specificity and high sensitivity is achieved, or the product becomes a tool for Thyroid Cancer related screening and evaluation.
Description
Technical Field
The invention relates to the fields of biology and doctors, in particular to a product, application and a method for thyroid cancer related screening and evaluation.
Background
Thyroid Cancer (TC) is the most common malignant neoplasm of the Thyroid gland, and includes four pathological types, papillary carcinoma, follicular carcinoma, undifferentiated carcinoma, and medullary carcinoma. In the modern society, the incidence rate of female thyroid cancer is high, and the incidence rate ratio of male thyroid cancer to female thyroid cancer is 1: about 4, the onset is common in young and strong years. Early stage thyroid cancer is mostly free of obvious symptoms and signs, and usually found as goiter by thyroid palpation and neck ultrasound examination at the time of physical examination. However, the existing ultrasonic resolution is low, so that benign and malignant thyroid nodules cannot be distinguished, and excessive diagnosis and treatment of the thyroid nodules are often caused. An efficient means for judging the benign and malignant thyroid nodules is clinically lacked, and a MALDI-TOF-MS thyroid cancer detection technology is formed, or becomes an efficient, noninvasive and low-cost detection means for judging the benign and malignant thyroid nodules, or has the potential for large-scale clinical early screening of the thyroid cancer.
Disclosure of Invention
The invention aims to solve the technical problem of the prior art and provides a product, application and a method for thyroid cancer related screening and evaluation.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a product for thyroid cancer screening, early diagnosis, risk assessment, the product being an operable system, the product comprising:
(S1) the nanometer material used for selectively enhancing the resolution of the metabolic molecule of the measured body fluid, and the matrix-assisted laser desorption ionization time-of-flight mass spectrometer used for measuring the metabolic molecule signal of the body fluid are used for measuring different metabolic signals of the body fluids of patients with different sources and healthy people through a core artificial intelligence classification algorithm;
(S2), a module and a processor for calculating the ratio of metabolic molecular composition and content of healthy humans to thyroid cancer;
(S3), optionally, a module and a processor for determining whether to suffer from thyroid cancer, assessing the risk of suffering from a tumor in a subject based on the composition and content of the metabolic molecules in the body fluid.
In the product for thyroid cancer screening, early diagnosis and risk assessment, the body fluid is selected from serum, plasma, saliva and urine.
In the product for thyroid cancer screening, early diagnosis and risk assessment provided by the invention, the reagent for determining body fluid metabolism in the step (S1) is a nano gold ball material, a matrix-assisted laser desorption ionization time-of-flight mass spectrum and a corresponding matched target plate.
The product for thyroid cancer screening, early diagnosis and risk assessment provided by the invention further comprises one or more of the following components:
a. reagents and instruments for collecting and processing a sample of a subject's bodily fluid;
b. reagents and instruments for separating and purifying serum/or plasma/or saliva/or urine;
c. reagents and instruments for separating and purifying serum/plasma/saliva/urine;
d. reagents and instruments for separating, purifying, enriching serum/plasma/saliva/urine;
e. the system comprises a database, a module and a processor for storing and processing metabolic molecular indexes of serum/plasma/saliva/urine of a subject;
f. a module and a processor for providing a decision threshold;
g. a module and a processor for comparing the metabolic molecular profile of the subject to a control to determine whether the subject suffers from thyroid cancer, to make a prognostic assessment or a risk assessment of suffering from thyroid cancer, to monitor a condition or to make a medical assessment;
h. a module and processor for providing a diagnosis, test result report;
j. instructions or instructions for use in which one or more of the following applications and decisions are described:
(i) for thyroid cancer screening test: when all detected molecular weights are 100-3000 daltons and the ratio between the number of metabolic molecules with a signal-to-noise ratio greater than 2.9 reaches or is higher than a predetermined threshold, determining that the subject has thyroid cancer or is at higher risk of having thyroid cancer;
(ii) for judgment of health and malignancy: when all detected molecular weights are 100-3000 daltons and the ratio between the number of metabolic molecules with a signal-to-noise ratio greater than 2.75 reaches or is higher than a preset threshold value, determining that the subject has thyroid cancer or is at risk of developing thyroid cancer;
(iii) for prognostic monitoring: when the detected molecular weights are 100-3000 daltons and the ratio of the number of the metabolic molecules with the signal-to-noise ratio larger than 2.5 reaches or is higher than a preset threshold value, the thyroid cancer of the subject is prompted to relapse or the thyroid cancer is possibly suffered;
(iv) thyroid carcinogenesis prediction for a subject population: when all detected molecular weights are 100-3000 daltons and the ratio of the number of the metabolic molecules with the signal-to-noise ratio larger than 2.3 reaches or is higher than a preset threshold value, indicating that the possibility of thyroid cancer of the subject is higher than that of other subjects;
(v) for monitoring the condition of thyroid cancer patients: when the detected molecular weight is 100-;
(vi) for efficacy assessment: the ratio of the number of all detected metabolic molecules with the molecular weight of 100-3000 daltons and the signal-to-noise ratio of more than 2.4 is measured and calculated at different time points before and after diagnosis and treatment or in the treatment process, and when the difference of the result higher than the result obtained by the previous measurement reaches or is higher than a preset range, the treatment effect of the therapy or the drug is poor.
In the product for thyroid cancer screening, early diagnosis and risk assessment, the preset threshold values in (i) - (iv) are determined by the optimal threshold values of 2.2-2.9, wherein the optimal threshold values are determined based on an artificial intelligence classification algorithm.
In the product for thyroid cancer screening, early diagnosis and risk assessment, the preset threshold value in (i) - (iv) is 2.2-2.9.
In the product for thyroid cancer screening, early diagnosis and risk assessment provided by the invention, in the step (vi), when the number of metabolic molecules with the signal-to-noise ratio of the detected molecular signal being more than 2.4 is higher than that obtained in the previous test, the condition of the patient is shown to be developed or further worsened.
In the product for thyroid cancer screening, early diagnosis and risk assessment provided by the invention, the ratio calculation of the number of molecules with signal-to-noise ratio higher than the optimal threshold value and the number of the selected detected metabolic molecules is carried out by adopting the following formula:
score ratio-number of molecules with signal to noise ratio above the optimal threshold/number of detected metabolic molecules.
The product for thyroid cancer screening, early diagnosis and risk assessment is used in a detection method comprising the following steps:
1. determining the level of a metabolic molecule in a plasma/serum/saliva/urine sample of a subject, said level of a metabolic molecule comprising: a metabolic molecule having a molecular weight of 100-;
2. calculating the ratio of the number of molecules with signal-to-noise ratio higher than the optimal threshold value to the number of detected metabolic molecules;
3. determining whether the subject has thyroid cancer based on the level of the metabolic molecule, performing a prognostic assessment or risk assessment of the subject for thyroid cancer, monitoring the condition of the subject, or assessing the efficacy of the treatment.
In the product for thyroid cancer screening, early diagnosis and risk assessment provided by the invention, the method further comprises one or more of the following steps:
1) collecting and processing a subject plasma/serum/saliva/urine sample;
2) separating and purifying serum/plasma/saliva/urine;
3) separating and purifying serum/plasma/saliva/urine;
4) separating, purifying, enriching serum/plasma/saliva/urine;
5) the metabolic molecule content ratio of the serum of the storage and processing object is used as an index of thyroid cancer related screening;
6) providing a judgment threshold value;
7) comparing the metabolic molecular composition content of the subject with a control to determine whether the subject suffers from thyroid cancer, to make a prognostic assessment or suffering from thyroid cancer, to monitor the condition of the subject, or to assess the efficacy of the treatment;
8) providing diagnosis and detection result report;
9) monitoring other thyroid cancer indexes, and combining the detection results of the other thyroid cancer indexes with the disease condition monitoring result.
The product for thyroid cancer screening, early diagnosis and risk assessment also comprises a kit, a device, a system and a combination thereof for detecting other thyroid cancer indexes.
In the product for thyroid cancer screening, early diagnosis and risk assessment provided by the invention, the index is selected from the following indexes: metabolic molecules of serum/plasma/saliva/urine of a patient.
In the product for thyroid cancer screening, early diagnosis and risk assessment provided by the invention, the basic condition of the patient is selected from the following: the number of molecules whose metabolic molecular signal-to-noise ratio is above an optimal threshold.
In the product for thyroid cancer screening, early diagnosis and risk assessment, the clinical tumor manifestation is selected from one or more of the following: completely healthy/abnormal thyroid nodules/confirmed thyroid cancer/thyroid cancer cure/thyroid cancer recurrence.
In the product for thyroid cancer screening, early diagnosis and risk assessment, the specific physicochemical examination index comprises a tumor biochemical index and medical image data, wherein the tumor biochemical index is selected from one or more of the following indexes: CEA, Tg, TSH in plasma, etc.
Use of an apparatus, module, and processor for the manufacture of a product for thyroid cancer screening, early diagnosis, prognosis evaluation, risk evaluation, condition monitoring, and efficacy evaluation in a subject, the product being a device, system, and combination thereof, the apparatus, module, and processor comprising:
A. reagents, instruments, modules and processors for determining the levels of serum/plasma/saliva/urine metabolic molecules for determining the composition and content of metabolic molecules;
B. optionally, a module or processor for calculating that the signal-to-noise ratio of the metabolic molecule is above a certain threshold;
C. optionally, a module or a processor for determining whether the subject suffers from thyroid cancer, performing a prognostic assessment or risk assessment of suffering from thyroid cancer, monitoring the condition of a disease or assessing the efficacy of a treatment based on the ratio of the signal to noise ratios.
The instrument, the module and the processor are applied to preparing products for thyroid cancer screening, early diagnosis, prognosis evaluation, risk evaluation, disease monitoring and curative effect evaluation of a target, wherein the instrument, the module and the processor are used for determining blood metabolites, and after the blood metabolites are combined with a nanogold ball material, matrix-assisted laser desorption ionization time-of-flight mass spectrometry is used for measuring signal-to-noise ratio data of the sample metabolites, and then a disease performance judgment and evaluation result is given based on an artificial intelligence algorithm.
Compared with the prior art, the invention has the advantages that: the invention develops a new method for diagnosing and typing thyroid cancer based on a small amount or trace (less than 5 mL) of body fluid samples (including plasma, serum, urine, saliva and the like). The method has the advantages that the accuracy (sensitivity and specificity) of thyroid cancer diagnosis is higher than that of the current clinical gold standard, the early thyroid cancer with thyroid nodules and thyroid lumps difficult to judge in the aspect of imaging can be identified, and the method has a prompt significance for benign and malignant tumors and pathogenic gene mutation carried by the tumors. In addition, compared with the existing method for detecting ultrasonic and biochemical indexes, the mass spectrum technology adopted by the invention has the advantages of shorter time consumption, no harm to human bodies, more convenient detection and greatly reduced cost.
Drawings
FIG. 1 is a schematic view of a sample collection device.
FIG. 2 is a schematic view of a sample storage device.
FIG. 3 is a schematic view of a sample preparation device.
FIG. 4 is a schematic diagram of a mass spectrometry data acquisition device.
FIG. 5 is a schematic diagram of the data generated by the mass spectrometric data acquisition apparatus.
FIG. 6 is a schematic diagram of a classification analysis of mass spectral data using an artificial intelligence algorithm.
FIG. 7 is a schematic diagram of the biological signal pathway for identifying relevant metabolite molecules that can be used for basic classification and studying the association of the metabolite molecules.
FIG. 8 is a flow chart of an algorithm for diagnosing, typing, and predicting which disease-causing genetic mutations are carried by a tumor for thyroid cancer.
Detailed Description
The technical solution adopted by the present invention will be further explained with reference to the schematic drawings.
The invention needs to obtain a high-accuracy and high-sensitivity prediction classification model which is based on a large number of real biological samples and can be used for repeated detection application, and the specific method comprises the following steps:
1. mixing a biological sample (blood plasma, blood serum, urine, saliva or the like) with a nano material for selectively enhancing the resolution of measuring the metabolism molecules of the body fluid, wherein the nano material comprises but is not limited to silicon and silicon compounds, gold, silver, platinum and other noble metals;
2. preparing the mixed sample on a target plate of a mass spectrum;
3. obtaining data (with accuracy of 0.001-0.1 Dalton) by using a mass spectrometer, wherein the obtained data is relative number value of the metabolic molecules with the length of more than 100 Dalton, and the data of all the metabolic molecules with the length of 100 Dalton and the signal-to-noise ratio of more than 2.2 are selected;
4. grouping and classifying the obtained data according to requirements, wherein the classification mode is as follows: diseased Vs healthy, metastatic Vs non-metastatic, types of gene mutations, etc.;
5. the data is classified using a machine learning algorithm, typically trained using 70% of the data taken randomly, tested using 30% of the data, and the model accuracy is cross-validated, where the purpose of data training and validation is: a high accuracy, high sensitivity predictive classification model based on a large number of real biological samples is obtained that can be used for repeated detection applications.
FIG. 1 represents the collection of serum or plasma or saliva or urine from a test person using a sample collection device; FIG. 2 is a schematic representation of the storage of collected samples using a sample storage device, the storage of collected samples at-80 ℃ and the transport to the corresponding detection laboratory; FIG. 3 is a schematic diagram of a sample preparation apparatus for mixing a sample with prepared nanomaterial to prepare the sample before processing; FIG. 4 is a schematic view of a mass spectrometry data acquisition device to obtain mass spectrometry data of a sample; FIG. 5 is a schematic diagram of the data generated by the mass spectrometric data acquisition device, which is a graph of the data generated by the mass spectrometric data acquisition device; FIG. 6 is a schematic diagram of a classification analysis of mass spectrometry data using an artificial intelligence algorithm; FIG. 7 is a schematic diagram of the biological signal pathway for identifying relevant metabolite molecules that can be used for basic classification and studying the association of the metabolite molecules. Fig. 1-7 are experimental and analytical routes for screening and evaluation related to thyroid cancer.
The invention utilizes MALDI-TOF-MS (Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) based on a new material to detect a large number of clinically confirmed thyroid cancer patients and plasma of non-thyroid cancer control population at high flux, and uses the obtained Mass data for machine learning.
The technology of the invention adopts laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) based on nanometer results (including but not limited to quantum dots, nanowires, nanospheres, nano hollow spheres, nano triangular shapes and the like) of nanometer materials (including but not limited to silicon and silicon compounds, gold, silver, platinum and other precious metals) to detect metabolites (substances with molecular weight below 3000 daltons) of plasma samples of a large number of thyroid cancer patients who have been diagnosed, and a set of brand-new algorithms for diagnosing and typing thyroid cancer and predicting which pathogenic gene mutation is carried by tumor are developed by learning big data by using a machine, wherein the overall flow chart of the algorithm is shown in FIG. 8, and the specific contents of the algorithm are as follows:
1) converting the raw data derived from the mass spectrometer (i.e. the aforementioned "relative number value of metabolic molecules above 100 daltons, we select 100-;
2) repeating the grouping of the data set processed in the step 1) for 10 times, wherein 30% of the groups are used as a test data set and 70% of the groups are used as a model training data set. A layered sampling method is adopted during grouping, so that the distribution of positive and negative samples in each group of data is consistent with the distribution of positive and negative samples in the total samples;
3) denoising and smoothing the data set processed in the step 2);
4) carrying out baseline calibration operation on the data set processed in the step 3);
5) carrying out standardization operation on the data set processed in the step 4) to obtain an integral mean value and variance parameters of the training set data;
6) aligning the data set processed in the step 5);
7) and repeating five-fold cross validation for the model training set data in the step 6) for 5 times, wherein the data are divided into a validation data set of 20% and a training data set of 80%. A layered sampling method is adopted during grouping, so that the distribution of positive and negative samples in each group of data is consistent with the distribution of positive and negative samples in the total samples;
8) training the data in the step 7) by using a classifier, outputting the average verification precision of the classifier model, and selecting the hyper-parameter of the classifier model when the verification precision is highest. The classifier model specifically adopts a Support Vector Machine (SVM), the SVM is a machine learning model utilizing hyperplane segmentation data, the SVM is generally applied to a two-classification problem under a supervised learning situation, a learning strategy is interval maximization, and SVM solution can be converted into a convex quadratic programming problem. The linear SVM is proposed by cortex and Vapnik in 1995, has great advantages in solving the problem of high-dimensional small sample classification, and can be popularized and applied to other machine learning problems such as function fitting and the like.
The idea of SVM classification is as follows: a hyperplane is found to segment the data (a straight line in the two-dimensional case) and then the segmentation of the data is maximized using the support vectors. The mathematical model is as follows:
simultaneously, the following requirements are met:
where the sample points of the data set T are hyperplanes. If the dataset T is linearly separable, then a maximum spaced separation hyperplane exists and is unique that can completely separate the samples in the dataset.
9) Putting the whole model training data set into the classifier model with the highest precision and the hyperparameter in the step 8) for training to obtain a final classifier model;
10) denoising and smoothing the model test set data obtained in the step 2);
11) carrying out baseline removal work on the data set processed in the step 10);
12) carrying out standardization operation on the data set processed in the step 11) by using the standardization parameters of the model training set data obtained in the step 5);
13) aligning the data set processed in the step 12);
14) putting the data set processed in the step 13) into the final classifier model in the step 9) for testing;
15) obtaining a predicted value of each sample in the test data set through the processing of the classifier in the step 14);
16) and comparing the predicted value obtained in the step 15) with the sample gold standard to obtain the average test error of the classifier model.
Steps 1) to 16) are detailed for the "high accuracy, high sensitivity predictive classification models based on large numbers of real biological samples that can be used for repeated detection applications" obtaining method.
Example 1: serum metabolic molecule time-of-flight mass spectrometry detection for screening/screening thyroid cancer
The method comprises the following steps of determining the content of 100-3000 Da metabolic molecules in a control serum sample and a thyroid cancer patient serum sample by adopting a nanogold ball material and a nanogold ball method, wherein the detection results are as follows:
1. by observing the metabolic molecular spectrogram of 100-3000 Da of serum samples of 500 patients in total, the number of the metabolic molecules with the signal-to-noise ratio of more than 2.9 can be found to be obviously different between thyroid cancer patients and controls.
2. Comparing the metabolic molecular maps of 500 healthy human serum samples of 100-3000 Da, and simultaneously carrying out comparison analysis on the number of metabolic molecules with the signal-to-noise ratio of a test subject being more than 2.9. The result shows that the metabolic molecular number of 100-3000 Da metabolic molecules with the signal-to-noise ratio larger than 2.9 is used as the thyroid cancer screening index, and the corresponding sensitivity is up to 95.4% under the condition that the specificity is controlled to be 98.5%. The index is highly accurate as a diagnosis index by referring to the judgment standard of the puncture tissue pathology.
3. Numerically, the difference between the metabolic molecules with the signal-to-noise ratio of greater than 2.9 in the 100-3000 Da metabolic molecules of thyroid cancer patients and the control samples is significant.
4. Meanwhile, with a threshold of 2.9 as a criterion for judging that the subject has thyroid cancer or is at risk of having thyroid cancer, the following table 1 is found:
TABLE 1
In the sample, the detection rate of thyroid cancer can reach about 95.4%;
the results show that the matrix-assisted laser desorption ionization time-of-flight mass spectrometry can be effectively used for screening thyroid cancer with high sensitivity and high specificity, and compared with the existing standard, the method and the index have higher accuracy. In addition, the method and the index of the invention can be used together with the existing standard to further improve the detection rate of thyroid cancer.
The above description is only a preferred embodiment of the present invention, and does not limit the present invention in any way. It will be understood by those skilled in the art that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (10)
1. A product for thyroid cancer screening, early diagnosis, risk assessment, the product being an operable system, the product comprising:
(S1) the nanometer material used for selectively enhancing the resolution of the metabolic molecule of the measured body fluid, and the matrix-assisted laser desorption ionization time-of-flight mass spectrometer used for measuring the metabolic molecule signal of the body fluid are used for measuring different metabolic signals of the body fluids of patients with different sources and healthy people through a core artificial intelligence classification algorithm;
(S2), a module and a processor for calculating the ratio of metabolic molecular composition and content of healthy humans to thyroid cancer patients;
(S3), optionally, a module and a processor for determining whether to suffer from thyroid cancer, assessing the risk of suffering from a tumor in a subject based on the composition and content of the metabolic molecules in the body fluid;
(S4), optionally, the product further comprises:
j. instructions or instructions for use in which one or more of the following applications and decisions are described:
(i) for thyroid cancer screening test: when all detected molecular weights are 100-3000 daltons and the ratio between the number of metabolic molecules with a signal-to-noise ratio greater than 2.9 reaches or is higher than a predetermined threshold, determining that the subject has thyroid cancer or is at higher risk of having thyroid cancer;
(ii) for judgment of health and malignancy: when all detected molecular weights are 100-3000 daltons and the ratio between the number of metabolic molecules with a signal-to-noise ratio greater than 2.75 reaches or is higher than a preset threshold value, determining that the subject has thyroid cancer or is at risk of developing thyroid cancer;
(iii) for prognostic monitoring: when the detected molecular weights are 100-3000 daltons and the ratio of the number of the metabolic molecules with the signal-to-noise ratio larger than 2.5 reaches or is higher than a preset threshold value, the thyroid cancer of the subject is prompted to relapse or the thyroid cancer is possibly suffered;
(iv) thyroid carcinogenesis prediction for a subject population: when the detected molecular weights are 100-3000 daltons and the ratio of the number of the metabolic molecules with the signal-to-noise ratio larger than 2.3 reaches or is higher than a preset threshold value, indicating that the possibility of thyroid cancer of the subject is higher than that of other subjects;
(v) for monitoring the condition of thyroid cancer patients: when the detected molecular weight is 100-;
(vi) for efficacy assessment: measuring and calculating the proportion of the number of all detected metabolic molecules with the molecular weight of 100-3000 daltons and the signal-to-noise ratio of more than 2.4 at different time points before and after diagnosis and treatment or in the treatment process, and when the difference of the result higher than the result obtained by the previous measurement reaches or is higher than a preset range, indicating that the treatment effect of the therapy or the medicament is poor;
the body fluid is selected from serum, plasma, saliva, urine;
the reagent for measuring the body fluid metabolism molecule in (S1) is a nanogold ball material.
2. The product of claim 1, further comprising one or more selected from the group consisting of:
a. reagents and instruments for collecting and processing a sample of a subject's bodily fluid;
b. reagents and instruments for separating and purifying serum/plasma/saliva/urine;
c. reagents and instruments for separating and purifying serum/plasma/saliva/urine;
d. reagents and instruments for separating, purifying, enriching serum/plasma/saliva/urine;
e. the system comprises a database, a module and a processor for storing and processing metabolic molecular indexes of serum/plasma/saliva/urine of a subject;
f. a module and a processor for providing a decision threshold;
g. a module and a processor for comparing the metabolic molecular profile of the subject to a control to determine whether the subject suffers from thyroid cancer, to make a prognostic assessment or a risk assessment of suffering from thyroid cancer, to monitor a condition or to make a medical assessment;
h. a module and a processor for providing diagnosis and detection result report.
3. The product of claim 1, wherein the predetermined threshold values in (i) - (iv) are determined by an optimal threshold value of 2.2-2.9, wherein the optimal threshold value is determined based on an artificial intelligence classification algorithm.
4. The product of claim 1, wherein (vi) the number of metabolic molecules whose signal-to-noise ratio of the detected molecular signal is greater than 2.4 is greater than that obtained in the previous test, indicating that the patient's condition has progressed or has further deteriorated.
5. A product according to claim 1, 3 or 4, wherein the calculation of the ratio of the number of molecules having a signal to noise ratio above an optimum threshold and the number of selected detected metabolic molecules is performed using the formula:
score ratio-number of molecules with signal to noise ratio above the optimal threshold/number of detected metabolic molecules.
6. The product of claim 1, wherein the product is used in a test method comprising the steps of:
1. determining the level of a metabolic molecule in a plasma/serum/saliva/urine sample of a subject, said level of a metabolic molecule comprising: a metabolic molecule having a molecular weight of 100-;
2. calculating the ratio of the number of molecules with signal-to-noise ratio higher than the optimal threshold value to the number of detected metabolic molecules;
3. determining whether the subject has thyroid cancer based on the level of the metabolic molecule, performing a prognostic assessment or risk assessment of the subject for thyroid cancer, monitoring the condition of the subject, or assessing the efficacy of the treatment.
7. The product of claim 6, wherein the method further comprises one or more of the following:
1) collecting and processing a subject plasma/serum/saliva/urine sample;
2) separating and purifying serum/plasma/saliva/urine;
3) separating and purifying serum/plasma/saliva/urine;
4) separating, purifying, enriching serum/plasma/saliva/urine;
5) storing and processing the metabolic molecule content ratio of the serum/plasma/saliva/urine of the object as an index for thyroid cancer related screening;
6) providing a judgment threshold value;
7) comparing the metabolic molecular composition content of the subject with a control to determine whether the subject suffers from thyroid cancer, to make a prognostic assessment or suffering from thyroid cancer, to monitor the condition of the subject, or to assess the efficacy of the treatment;
8) providing diagnosis and detection result report;
9) monitoring other thyroid cancer indexes, and combining the detection results of the other thyroid cancer indexes with the disease condition monitoring result.
8. The product of claim 1, further comprising kits, devices, systems, and combinations thereof for detecting other thyroid cancer indicators.
9. The product of claim 8, wherein the indicator is selected from the group consisting of: metabolic molecules of serum/plasma/saliva/urine of the patient;
the patient's basic condition is selected from the following: the number of molecules whose metabolic molecular signal-to-noise ratio is above an optimal threshold;
the clinical presentation of the tumor is selected from one or more of the following: completely healthy/abnormal thyroid nodules/confirmed thyroid cancer/thyroid cancer cure/thyroid cancer recurrence;
the specific physicochemical examination index comprises a tumor biochemical index and a medical image index, wherein the tumor biochemical index is selected from one or more of the following indexes: CEA, Tg, TSH in serum.
10. Use of an apparatus, module and processor for the manufacture of a product for thyroid cancer screening, early diagnosis, prognosis evaluation, risk evaluation, condition monitoring and efficacy evaluation in a subject, wherein the product is a device, system and combination thereof, the apparatus, module and processor comprising:
A. reagents, instruments, modules and processors for determining the levels of serum/plasma/saliva/urine metabolic molecules for determining the composition and content of metabolic molecules;
B. optionally, a module or processor for calculating that the signal-to-noise ratio of the metabolic molecule is above a certain threshold;
C. optionally, a module or processor for determining whether the subject suffers from thyroid cancer, performing a prognostic assessment or risk assessment of suffering from thyroid cancer, monitoring a condition or assessing a therapeutic effect of the subject based on the ratio of the signal-to-noise ratios;
and (A) after the blood metabolite is combined with the nano gold ball material, matrix-assisted laser desorption ionization time-of-flight mass spectrometry is used for determining the blood metabolite, the signal-to-noise ratio data of the sample metabolite is measured, and then a disease performance judgment and evaluation result is given based on an artificial intelligence algorithm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910420650.4A CN111965240A (en) | 2019-05-20 | 2019-05-20 | Product, application and method for thyroid cancer related screening and assessment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910420650.4A CN111965240A (en) | 2019-05-20 | 2019-05-20 | Product, application and method for thyroid cancer related screening and assessment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111965240A true CN111965240A (en) | 2020-11-20 |
Family
ID=73357864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910420650.4A Pending CN111965240A (en) | 2019-05-20 | 2019-05-20 | Product, application and method for thyroid cancer related screening and assessment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111965240A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113030235A (en) * | 2021-04-20 | 2021-06-25 | 中国医学科学院北京协和医院 | Product and method for differential diagnosis and evaluation of thyroid cancer |
| CN113514530A (en) * | 2020-12-23 | 2021-10-19 | 岛津企业管理（中国）有限公司 | Thyroid malignant tumor diagnosis system based on open ion source |
| CN114438212A (en) * | 2022-02-18 | 2022-05-06 | 中国人民解放军军事科学院军事医学研究院 | Serum miRNA combination for thyroid tumor diagnosis, 131 iodine treatment and prognosis |
-
2019
- 2019-05-20 CN CN201910420650.4A patent/CN111965240A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113514530A (en) * | 2020-12-23 | 2021-10-19 | 岛津企业管理（中国）有限公司 | Thyroid malignant tumor diagnosis system based on open ion source |
| CN113030235A (en) * | 2021-04-20 | 2021-06-25 | 中国医学科学院北京协和医院 | Product and method for differential diagnosis and evaluation of thyroid cancer |
| CN113030235B (en) * | 2021-04-20 | 2022-03-22 | 中国医学科学院北京协和医院 | Product and method for differential diagnosis and evaluation of thyroid cancer |
| CN114438212A (en) * | 2022-02-18 | 2022-05-06 | 中国人民解放军军事科学院军事医学研究院 | Serum miRNA combination for thyroid tumor diagnosis, 131 iodine treatment and prognosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mayeux | Biomarkers: potential uses and limitations | |
| Drake et al. | Discriminant analysis of trace element distribution in normal and malignant human tissues | |
| KR102291105B1 (en) | Method and System of Providing Cancer Diagnosis Information Using Artificial Intelligence-Based Liquid Biopsy by Exosomes | |
| Waltman et al. | Exhaled-breath testing for prostate cancer based on volatile organic compound profiling using an electronic nose device (Aeonose™): a preliminary report | |
| CN111965240A (en) | Product, application and method for thyroid cancer related screening and assessment | |
| CN104204798A (en) | Biomarkers for bladder cancer and methods using the same | |
| JP2008542742A (en) | Biomarker | |
| Ralbovsky et al. | Analysis of individual red blood cells for Celiac disease diagnosis | |
| JP2019168319A (en) | Marker for metabolite in urine for inspecting childhood cancer | |
| KR102635700B1 (en) | Cancer risk assessment method and cancer risk assessment system | |
| JP6082478B2 (en) | Cancer evaluation method and cancer evaluation system | |
| Liu et al. | A carbon-based polymer dot sensor for breast cancer detection using peripheral blood immunocytes | |
| CN112748191A (en) | Small molecule metabolite biomarker for diagnosing acute diseases, and screening method and application thereof | |
| CN113913333B (en) | Lung cancer diagnosis marker and application | |
| CN110501443B (en) | Novel biomarker for noninvasive identification/early warning of fatty liver cows | |
| CN113567585A (en) | Esophageal squamous carcinoma screening marker and kit based on peripheral blood | |
| CN111965235A (en) | Products, uses and methods for pancreatic cancer-related screening and assessment | |
| CN111965241A (en) | Products, uses and methods for ovarian cancer-related screening and assessment | |
| CN111965238A (en) | Products, uses and methods for non-small cell lung cancer-related screening and assessment | |
| CN111965233A (en) | Product, application and method for breast cancer related screening and assessment | |
| CN111965234A (en) | Products, uses and methods for prostate cancer-related screening and assessment | |
| CN111965242A (en) | Products, uses and methods for hepatocellular carcinoma-related screening and assessment | |
| CN111965239A (en) | Products, uses and methods for gastric cancer-related screening and assessment | |
| CN111965236A (en) | Product, application and method for pheochromocytoma and paraganglioma related screening and evaluation | |
| CN111965237A (en) | Product, application and method for colorectal cancer related screening and assessment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201120 |
|
| WD01 | Invention patent application deemed withdrawn after publication |